Supernus Pharma (SUPN) Cited for Making False or Misleading Claims About Risks Associated with Oxtellar XR

November 3, 2016 10:49 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Supernus Pharma (NASDAQ: SUPN) received a letter from the FDA for making false or misleading claims about risks associated with Oxtellar XR.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Trader Talk

Add Your Comment